Birdwatch Note
2024-09-25 11:57:50 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
米国の売上上位8位のうちの3つが抗がん剤であり、近年は治療成績も格段に上がっています https://news.yahoo.co.jp/expert/articles/1b191a2ed5889e97d4311826f130aa016629b2a8 世界の医薬品の売り上げTOP10の半分が抗がん剤です https://answers.ten-navi.com/pharmanews/16470/ WHOは必須医薬品リストに抗がん剤を掲載しています https://www.who.int/europe/news-room/fact-sheets/item/cancer-treatment 米国国立がん研究所所長(当時)DeVita氏は、がん死亡減少の半分の原因は主に化学療法を含むがん治療の進歩によるとしています https://doi.org/10.1158/0008-5472.CAN-07-6611 https://en.wikipedia.org/wiki/Vincent_T._DeVita 科学的根拠に基づかない主張の目的は偽医療への誘導です。 日本人が欧米事情等に疎いことは昔から偽医療利権に悪用されています https://youtu.be/nySPY7eH9IU https://cancer.jpn.org/static/fake_medicine.html https://cancer.jpn.org/static/ota_h_405_unconventional_cancer_treatments.html 代替医療にがんの治療効果はありません https://doi.org/10.1093/jnci/djx145 https://doi.org/10.1001/jamaoncol.2018.2487 https://en.wikipedia.org/wiki/National_Center_for_Complementary_and_Integrative_Health
Written by EE7192EF0B1C47D8A3430C3E070DA2A0BFAA58717F9133404318E9D7666B1A00
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1838786750954770617
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1838910782886777214
- noteId - 1838910782886777214
- participantId -
- noteAuthorParticipantId - EE7192EF0B1C47D8A3430C3E070DA2A0BFAA58717F9133404318E9D7666B1A00 Participant Details
- createdAtMillis - 1727265470606
- tweetId - 1838786750954770617
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- 米国の売上上位8位のうちの3つが抗がん剤であり、近年は治療成績も格段に上がっています https://news.yahoo.co.jp/expert/articles/1b191a2ed5889e97d4311826f130aa016629b2a8 世界の医薬品の売り上げTOP10の半分が抗がん剤です https://answers.ten-navi.com/pharmanews/16470/ WHOは必須医薬品リストに抗がん剤を掲載しています https://www.who.int/europe/news-room/fact-sheets/item/cancer-treatment 米国国立がん研究所所長(当時)DeVita氏は、がん死亡減少の半分の原因は主に化学療法を含むがん治療の進歩によるとしています https://doi.org/10.1158/0008-5472.CAN-07-6611 https://en.wikipedia.org/wiki/Vincent_T._DeVita 科学的根拠に基づかない主張の目的は偽医療への誘導です。 日本人が欧米事情等に疎いことは昔から偽医療利権に悪用されています https://youtu.be/nySPY7eH9IU https://cancer.jpn.org/static/fake_medicine.html https://cancer.jpn.org/static/ota_h_405_unconventional_cancer_treatments.html 代替医療にがんの治療効果はありません https://doi.org/10.1093/jnci/djx145 https://doi.org/10.1001/jamaoncol.2018.2487 https://en.wikipedia.org/wiki/National_Center_for_Complementary_and_Integrative_Health
Note Ratings
| rated at | rated by | |
| 2024-09-30 09:43:24 -0500 | Rating Details | |
| 2024-09-27 16:42:54 -0500 | Rating Details | |
| 2024-09-27 03:40:20 -0500 | Rating Details | |
| 2024-09-26 21:04:55 -0500 | Rating Details | |
| 2024-09-26 18:26:37 -0500 | Rating Details | |
| 2024-09-26 09:59:48 -0500 | Rating Details | |
| 2024-09-26 06:27:55 -0500 | Rating Details | |
| 2024-09-25 20:34:50 -0500 | Rating Details | |
| 2024-09-25 19:43:59 -0500 | Rating Details | |
| 2024-09-25 19:35:56 -0500 | Rating Details | |
| 2024-09-25 19:18:52 -0500 | Rating Details | |
| 2024-09-25 18:36:07 -0500 | Rating Details | |
| 2024-09-25 17:56:52 -0500 | Rating Details | |
| 2024-09-25 17:35:34 -0500 | Rating Details | |
| 2024-09-25 16:55:41 -0500 | Rating Details | |
| 2024-09-25 16:51:07 -0500 | Rating Details | |
| 2024-09-25 16:43:46 -0500 | Rating Details | |
| 2024-09-25 16:08:52 -0500 | Rating Details | |
| 2024-09-25 14:48:19 -0500 | Rating Details | |
| 2024-09-25 13:52:54 -0500 | Rating Details | |
| 2024-09-25 13:33:40 -0500 | Rating Details | |
| 2024-09-25 11:31:29 -0500 | Rating Details | |
| 2024-09-25 11:28:57 -0500 | Rating Details | |
| 2024-09-25 10:53:55 -0500 | Rating Details | |
| 2024-09-25 10:53:50 -0500 | Rating Details | |
| 2024-09-25 10:48:35 -0500 | Rating Details | |
| 2024-09-25 10:43:46 -0500 | Rating Details | |
| 2024-09-25 09:33:43 -0500 | Rating Details | |
| 2024-09-25 09:28:33 -0500 | Rating Details | |
| 2024-09-25 09:25:16 -0500 | Rating Details | |
| 2024-09-25 09:16:14 -0500 | Rating Details | |
| 2024-09-25 09:14:57 -0500 | Rating Details | |
| 2024-09-25 09:08:48 -0500 | Rating Details | |
| 2024-09-25 09:08:48 -0500 | Rating Details | |
| 2024-09-25 08:44:30 -0500 | Rating Details | |
| 2024-09-25 08:31:16 -0500 | Rating Details | |
| 2024-09-25 08:28:20 -0500 | Rating Details | |
| 2024-09-25 08:26:42 -0500 | Rating Details | |
| 2024-09-25 08:22:21 -0500 | Rating Details | |
| 2024-09-25 08:20:13 -0500 | Rating Details | |
| 2024-09-25 08:16:30 -0500 | Rating Details | |
| 2024-09-25 08:12:40 -0500 | Rating Details | |
| 2024-09-25 08:11:15 -0500 | Rating Details | |
| 2024-09-25 08:10:45 -0500 | Rating Details | |
| 2024-09-25 08:10:38 -0500 | Rating Details | |
| 2024-09-25 08:10:15 -0500 | Rating Details | |
| 2024-09-25 08:08:40 -0500 | Rating Details | |
| 2024-09-25 08:07:43 -0500 | Rating Details | |
| 2024-09-25 08:02:09 -0500 | Rating Details | |
| 2024-09-25 07:53:27 -0500 | Rating Details | |
| 2024-09-25 07:51:34 -0500 | Rating Details | |
| 2024-09-25 07:47:43 -0500 | Rating Details | |
| 2024-09-25 07:47:34 -0500 | Rating Details | |
| 2024-09-25 07:44:43 -0500 | Rating Details | |
| 2024-09-25 07:43:53 -0500 | Rating Details | |
| 2024-09-25 07:42:37 -0500 | Rating Details | |
| 2024-09-25 07:41:39 -0500 | Rating Details | |
| 2024-09-25 07:25:08 -0500 | Rating Details | |
| 2024-09-25 07:15:24 -0500 | Rating Details | |
| 2024-09-25 07:08:13 -0500 | Rating Details | |
| 2024-09-25 07:06:36 -0500 | Rating Details | |
| 2024-09-25 07:05:29 -0500 | Rating Details | |
| 2024-09-25 07:04:26 -0500 | Rating Details | |
| 2024-09-25 07:00:26 -0500 | Rating Details | |
| 2024-10-03 12:55:26 -0500 | Rating Details | |
| 2024-10-22 10:23:07 -0500 | Rating Details | |
| 2024-09-26 00:20:20 -0500 | Rating Details | |
| 2024-09-25 15:50:28 -0500 | Rating Details | |
| 2024-09-25 12:04:24 -0500 | Rating Details | |
| 2024-09-25 11:33:51 -0500 | Rating Details | |
| 2024-09-25 09:35:17 -0500 | Rating Details | |
| 2024-09-25 09:30:56 -0500 | Rating Details | |
| 2024-09-25 09:05:22 -0500 | Rating Details | |
| 2024-09-25 08:41:51 -0500 | Rating Details | |
| 2024-09-25 08:35:40 -0500 | Rating Details | |
| 2024-09-25 08:07:09 -0500 | Rating Details | |
| 2024-09-25 07:57:02 -0500 | Rating Details | |
| 2024-09-25 07:43:27 -0500 | Rating Details |